Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy
Tumori 2017; 103(2): 204 - 208
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsBurak Arslan, Özkan Onuk, İsmet Hazar, Muammer Aydın, Nusret Can Çilesiz, Ali Eroglu, Barış Nuhoglu
To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa).
A total of 86 patients with localized prostate cancer were treated with open radical prostatectomy (RP). The control group included 80 patients who were referred to the urology outpatient clinic with normal rectal examination and prostate-specific antigen (PSA) levels. The patients’ characteristics, baseline PSA value, and serum endocan levels were recorded. The patients were followed up with the measurement of PSA concentration every 3 months during the first year, thereafter every 6 months until 5 years, then yearly after surgery. The primary endpoint of follow-up was the time of biochemical recurrence.
The median serum endocan levels were 3.14 ng/mL in the RP group and 2.98 ng/mL in the control group (p = 0.122). A total of 86 patients who underwent RP for PCa were divided into 2 groups based on a cutoff serum endocan level of 1.8 ng/mL. The distribution of Gleason score and biochemical failure rate were significantly higher in patients with serum endocan ≥1.8 ng/mL (p = 0.031 and p = 0.047). The biochemical recurrence-free time for endocan ≥1.8 ng/mL and <1.8 ng/mL were 38 and 56 months, respectively (p = 0.041). Spearman correlation analysis showed a linear relationship between endocan expression and Gleason score (p = 0.025, p = 0.511). Multivariate analysis revealed that elevated serum endocan level (≥1.8 ng/mL) was a significant predictor of biochemical progression-free survival (hazard ratio 2.44; 95% confidence interval 1.78-3.23; p = 0.001).
The current study indicates that endocan has a close relationship with tumor recurrence in PCa.
- • Accepted on 28/04/2016
- • Available online on 25/07/2016
- • Published in print on 24/03/2017
This article is available as full text PDF.
- Arslan, Burak [PubMed] [Google Scholar] , * Corresponding Author (email@example.com)
- Onuk, Özkan [PubMed] [Google Scholar]
- Hazar, İsmet [PubMed] [Google Scholar]
- Aydın, Muammer [PubMed] [Google Scholar]
- Çilesiz, Nusret Can [PubMed] [Google Scholar]
- Eroglu, Ali [PubMed] [Google Scholar]
- Nuhoglu, Barış [PubMed] [Google Scholar]
Department of Urology, Istanbul Taksim Training and Research Hospital, Istanbul - Turkey